11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The proposed study aims to use 11C-acetate PET/CT to preliminarily test and validate methods
for imaging astrocyte activation as an early indicator of neuroinflammation in Alzheimer's
disease (AD). 11C-Acetate PET/CT has been shown to quantify astrocyte activation in vivo, but
no reports have evaluated its potential in AD. The investigators propose to test 11C-Acetate
PET/CT as a marker for astrocyte activation associated with pathologic amyloid deposition in
AD. The investigators will compare binding between subjects with early stage AD and healthy
controls. Further, the investigators will investigate the correlation between amyloid and
acetate binding. If the investigators find increased astrocyte activation in response to
cerebral amyloid by showing a group difference in brain acetate uptake between disease and
controls or a strong correlation between acetate and amyloid PET/CT binding. Validating
neuroinflammation markers in AD ultimately may guide therapeutic modulation of beneficial and
damaging neuroinflammation to slow disease progression, as well as providing new insights
into AD pathophysiology.